世界の肝腎症候群市場の規模、シェア、トレンド分析レポート – 業界の概要と2032年までの予測

肝腎症候群市場分析

肝腎症候群市場は、診断の進歩、意識の高まり、肝硬変や肝炎などの肝疾患の罹患率の上昇に牽引され、成長を遂げています。肝腎症候群は、進行した肝疾患の患者に起こる重度の腎機能障害であり、重大な罹患率と死亡率につながります。この市場には、バソプレシン類似体、血漿増量剤、肝移植などの外科的介入などの治療法が含まれます。腎灌流を標的とした革新的な治療法や診断ツールの改善などの最近の進歩は、患者の転帰を改善しています。新興のバイオ医薬品企業は新しい治療法に注力しており、市場成長の新たな機会を生み出しています。さらに、政府の支援プログラムと医療費の増加により、先進地域と新興地域の両方で導入が進んでいます。しかし、治療費の高さや低所得国でのアクセスの制限などの課題は、依然として大きな制約となっています。全体として、市場は技術の進歩と研究開発への投資の増加に支えられ、拡大する態勢が整っています。

肝腎症候群の市場規模

世界の肝腎症候群の市場規模は、2024年に14億4,000万米ドルと評価され、2025年から2032年の予測期間中に7.04%のCAGRで成長し、2032年までに24億8,000万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

肝腎症候群の市場動向

「診断と効果的な治療法の開発」

肝腎症候群市場は、治療戦略と診断技術の進歩により進化しています。肝腎症候群は進行した肝疾患に関連する生命を脅かす腎機能障害であり、正確な診断と効果的な治療が必要です。バソプレシン類似体と血漿量増量剤の革新により、腎灌流が促進され、患者の転帰が改善されています。注目すべき傾向として、肝臓と腎臓の両方の合併症に対処する併用療法にますます重点が置かれ、総合的な患者ケアが提供されています。さらに、バイオマーカーや画像技術などの非侵襲性診断技術の採用により、早期発見が合理化されています。意識の高まり、研究への投資、および支援的な医療政策により、市場は拡大し、進行した肝疾患の患者の満たされていないニーズに対応します。

レポートの範囲と肝腎症候群市場のセグメンテーション      

肝腎症候群市場の定義

肝腎症候群は、肝硬変や急性肝不全などの進行した肝疾患を患っている人に起こる、急速かつ進行性の腎不全を特徴とする重篤な病状です。この症候群は、構造的損傷を伴わずに腎臓への血流が減少することで起こり、多くの場合、肝機能障害、感染症、出血が原因となります。この病状は生命を脅かすものであり、通常は尿量の減少、体液貯留、血清クレアチニン値の上昇として現れます。

肝腎症候群の市場動向

ドライバー

• 肝臓疾患の罹患率の上昇

肝硬変、肝炎、非アルコール性脂肪性肝疾患 (NAFLD) などの慢性肝疾患の罹患率の上昇は、肝腎症候群の治療市場にとって大きな推進力となっています。これらの肝疾患は、肝腎症候群などの合併症が現れる段階にまで進行することが多く、迅速かつ効果的な医療介入が必要になります。アルコール摂取、肥満、ウイルス感染などの要因により、肝疾患の世界的な負担がさらに増大し、先進的な治療法の需要が高まっています。製薬会社や医療提供者がこの重大かつ増大するニーズへの対応に取り組んでいるため、肝腎症候群市場の成長にとって好ましい環境が生まれています。

• 革新的な治療法の開発

The development of innovative therapies, such as vasopressin analogs and plasma volume expanders, is a key market driver for hepatorenal syndrome treatment. These advanced treatments are designed to improve renal perfusion and stabilize kidney function in patients with severe liver-related kidney failure. By addressing the root causes of reduced renal blood flow, these therapies enhance patient outcomes, reduce mortality rates, and improve quality of life. The growing focus on research and development in this area has resulted in a pipeline of promising new drugs and treatment protocols, fostering market growth.

Opportunities

• Advancements in Personalized Medicine

The growing adoption of personalized treatment approaches presents a significant opportunity for the hepatorenal syndrome market. Advancements in genetic testing and biomarker identification enable healthcare providers to develop tailored therapies based on individual patient profiles. This precision medicine approach improves treatment efficacy, minimizes adverse effects, and enhances patient outcomes. Personalized treatments also facilitate early intervention by identifying at-risk individuals before symptoms worsen. As research in this area continues to expand, pharmaceutical companies can leverage these advancements to create innovative solutions. This trend meets the rising demand for targeted therapies and drives market growth by delivering better healthcare outcomes.

• Rise in Liver Transplant Programs

The increasing availability of liver transplantation as a definitive treatment option for patients with hepatorenal syndrome presents a significant market opportunity. As liver transplant programs expand globally, there is growing demand for pre- and post-transplant care solutions, such as immunosuppressive therapies, monitoring tools, and supportive treatments to manage the complex patient needs. These therapies help improve transplant success rates, manage complications, and enhance recovery. As the number of liver transplants increases, pharmaceutical companies and healthcare providers have new opportunities. They can develop comprehensive care regimens that address the full continuum of care, thereby expanding the market for hepatorenal syndrome treatments.

Restraints/Challenges

• Limited Treatment Options

While significant advancements have been made in the treatment of hepatorenal syndrome, the available options remain limited, posing a challenge for market growth. Current therapies, such as vasopressin analogs and plasma volume expanders, offer temporary relief but are not long-term solutions. There is a lack of therapies that can effectively address the underlying causes and provide sustained kidney function recovery in patients with advanced liver disease. This gap in effective long-term treatments creates a challenge for the hepatorenal syndrome market.

•  High Cost of Treatment

Innovative treatments for hepatorenal syndrome, such as vasopressin analogs and plasma volume expanders, offer significant benefits but come at a high cost, which presents a major restraint for the market. These therapies, while effective, can be prohibitively expensive, limiting their accessibility to patients in low-income and developing regions. The high cost of these treatments can lead to disparities in healthcare access, making it difficult for underserved populations to receive the necessary care. As a result, the widespread adoption of these advanced therapies is slowed, hindering the overall growth of the hepatorenal syndrome market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hepatorenal Syndrome Market Scope

The market is segmented on the basis of type, diagnosis, medication, surgical therapies, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Type 1 Hepatorenal Syndrome
• Type 2 Hepatorenal Syndrome
• Others

Diagnosis

• Complete Blood Cell Count
• Liver Function Tests
• Urinalysis and Urine Electrolytes
• Others

Medication

• Vasopressin Analogues
• Sympathomimetic Agents
• Plasma Volume Expanders
• Others

Surgical Therapies

• Peritoneovenous Shunting
• Surgical Shunts
• Liver Transplantation
• Others

Route of Administration

• Oral
• Injectable
• Others

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Hepatorenal Syndrome Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, diagnosis, medication, surgical therapies, route of administration, end users, and distribution channel referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the hepatorenal syndrome market due to the early adoption of cutting-edge technologies, a high prevalence of liver diseases, and the presence of key pharmaceutical companies. The region benefits from a well-established healthcare infrastructure and significant investments in research and development. These factors contribute to the market's expansion and the introduction of innovative treatments for hepatorenal syndrome.

The Asia-Pacific region is expected to experience significant growth during the forecast period, achieving the highest CAGR. This growth is driven by increasing investments in healthcare infrastructure, a rising prevalence of kidney disorders, and a growing elderly population. Additionally, the region's expanding research and development efforts focused on liver disease treatment and management are further fueling market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Hepatorenal Syndrome Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Hepatorenal Syndrome Market Leaders Operating in the Market Are:

• Mallinckrodt (U.S.)
• Lupin (India)
• Salix Pharmaceuticals (U.S.)
• Norgine (U.K.)
• ASKA Pharmaceutical Co., Ltd. (Japan)
• Bausch Health Companies Inc. (Canada)
• Swedish Orphan Biovitrum AB (U.S.)
• Umecrine Cognition AB (Sweden)
• Kannalife Sciences, Inc. (U.S.)
• Ferring (Switzerland)
• Merck KGaA (Germany)
• アムジェン社（米国）
• ファイザー社（米国）
• GSK plc. (英国)
• 武田薬品工業株式会社（日本）
• メルク社（米国）
• ヤンセンファーマシューティカルズ（米国）
• エーザイ株式会社（日本）
• ヤンセンファーマシューティカルズ（米国）
• アッヴィ社（米国）
• BioVie Inc.（米国）
• カンバーランド・ファーマシューティカルズ社（米国）
• ORPHAN THERAPEUTICS, LLC (米国)
• Noorik Biopharmaceuticals AG (スイス)
• PharmaIN, Corp.（米国）
• ヒクマ・ファーマシューティカルズPLC（英国）

肝腎症候群市場の最新動向

• 2024年10月、世界的な専門医薬品会社であるマリンクロット社は、2024年腎臓週間で注射用TERLIVAZ®（テルリプレシン）に関するポスター発表を行うと発表した。発表では、腎機能が急速に低下している肝腎症候群（HRS）患者への使用に焦点を当てた。このイベントは、2024年10月23日から27日までサンディエゴで開催された米国腎臓学会（ASN）の年次総会中に行われた。

SKU-50419